Key result
Potential drug-drug interactions were identified in 91% of chronic kidney disease patients, with age and concomitant drugs significantly associated with the number of interactions (p<0.05).
Why the study?
Polypharmacy in CKD increases the risk of adverse drug reactions, but no published studies had evaluated the prevalence of potential drug-drug interactions among CKD patients in any European country.
What is the prevalence of potential drug-drug interactions among chronic kidney disease patients?
Cross-Sectional (n=112)
No
What is the prevalence of potential drug-drug interactions among chronic kidney disease patients?
There is a high prevalence of potential drug-drug interactions among CKD patients, highlighting the need for interaction-checking programs in clinical practice to avoid serious adverse effects.
Answers are grounded in this paper and cite their sources.
High DDI prevalence in CKD linked to age and polypharmacy; hypothesis-generating for screening programs, requiring prospective validation before practice change.
Chronic kidney disease (CKD) is a major health problem worldwide and, in Spain, it is present in 15.1% of individuals. CKD is frequently associated with some comorbidities and patients need to be prescribed multiple medications. Polypharmacy increases the risk of adverse drug reactions (ADRs). There are no published studies evaluating the prevalence of potential drug–drug interactions (pDDIs) among CKD patients in any European country. This study was aimed to determine the prevalence, pattern, and factors associated with pDDIs among CKD patients using a drug interactions program. An observational cross-sectional study was carried out at Plasencia Hospital, located in Spain. Data were collected among patients with CKD diagnoses and pDDIs were assessed by the Lexicomp® Drug Interactions platform. Data were obtained from 112 CKD patients. A total number of 957 prescribed medications were acknowledged, and 928 pDDIs were identified in 91% of patients. Age and concomitant drugs were significantly associated with the number of pDDIs (p < 0.05). According to the results, the use of programs for the determination of pDDIs (such as Lexicomp®) is recommended in the clinical practice of CKD patients in order to avoid serious adverse effects, as is paying attention to contraindicated drug combinations.
No takes yet. Share an insight, caveat, or question.
Santos-Díaz et al. (2020) conducted a cross-sectional in Chronic kidney disease (n=112). Multiple medications (polypharmacy) was evaluated on Prevalence of potential drug-drug interactions (pDDIs) (p=<0.05). Potential drug-drug interactions were identified in 91% of chronic kidney disease patients, with age and concomitant drugs significantly associated with the number of interactions (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: